Fed Chair “Uncle Jerry” Powell Remind Hawkish As Stocks Move Lower on Wednesday – $APLS $BHC $KVYO $VIX Rise!

By John F. Heerdink, Jr.

Quote of the Day — “To begin, begin.” – William Wordsworth

Happy Hump Day!

I hope that the middle of the week has treated you well.

Today, I travelled to beautiful Salt Lake City, UT to attend our sister organzation Tribe Public’s CEO Presentation and Q&A Luncheon Event with Jeffrey Meckler, CEO of Indaptus Therapeutics (INDP, $3.50), a company with the ability to harness both the body’s innate and adaptive immune responses & believes that they are uniquely positioned to revolutionize the treatment of cancer and certain infectious diseases. On Sept. 19, Indaptus announced dosing of the first patient in the second cohort of patients to receive a single dose of Decoy20 in the INDP-D101 trial. This cohort dose is a dose reduction from the previous cohort based on the significant pharmacodynamic effect seen with the first cohort and anticipated optimal Decoy20 safety profile for both weekly dosing and combination approaches. Dr. Roger Waltzman, Indaptus’ Chief Medical Officer stated, “This cohort is important to the development of Decoy20 as it may provide sufficient data for us to move Decoy20 to a multi-dosing regimen. To date, we have seen positive signs of an immune response with an anticipated adverse effect profile, and we look forward to seeing whether this lower dose provides similar evidence of increased cytokines that can trigger both innate and adaptive immune responses.” Jeffrey Meckler, Chief Executive Officer stated,“We continue to be encouraged by the initial results of the first cohort and look forward to progressing into the multi-dosing regimen as soon as we have enough data. The study’s objectives are to assess the safety and tolerability of Decoy20, to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D), as well as to assess Decoy20 pharmacokinetics (PK), pharmacodynamics and clinical activity. The Phase 1 study was initiated with a single dose escalation, which is planned to be followed by an expansion with continuous weekly administration of Decoy20. The study is enrolling patients with advanced/metastatic solid tumors, who have exhausted approved treatment options. More information can be found at www.clinicaltrials.gov.

As for the broad stock market, investors experienced a relatively down day that was primarily led by the trials and tribulations relayed at the FOMC meeting where Fed Chair “Uncle Jerry” Powell decided to keep interest rates as is, but signaled there would be one more this year and that they are not expecting to cut rates next year. The macroeconomic schedule also produced the weekly MBA Mortgage Applications Index report that shoed a moved up to 5.4%, while refinance applications jumped a cool 13% & purchase applications bumped up 2%. The weekly EIA crude oil inventories report confirmed a 2.14M barrel draw as oil prices pulled back 1.02% closing at $90.27/bbl. The 2-yr note closed at 5.13% up 1bp & the 10-yr note closing at 4.35%, down 2bps. The US dollar index ended higher at $105.35, +.14%.

At the end of today’s session the Dow 30 closed at 34,440.88 (-.22%). The S&P 500 closed at 4,402.20 (-.94%) with a majority of the sectors closing in the red and with the influential communication services sector down 1.9% and the information technology sector off 1.8% leading the all lower. The Nasdaq moved further below the 14k level closing at 13,469.13 (-1.53%), while Cathie Wood’s ARK Innovation ETF (ARKK) closed at $40.78, -1.76%. The Magnificent Seven closed across the board as follows: Alphabet (GOOG) closing at $134.59, -3.05%, Amazon (AMZN) closing at $135.29, -1.70%, Apple (AAPL) closing at $175.49, -2%, Meta Platforms (META) closing at $299.67, -1.77%, Microsoft (MSFT) closing at $320.77, -.2.40%, NVIDIA (NVDA) closing at $422.39, -2.94% & Tesla (TSLA) closing at $262.59, -1.47% today.

Today, for a second day in a row, the markets produced another significant IPO, this time Klaviyo, Inc. (NYSE: KVYO, $32.76, +9.20%), the company that powers smarter digital relationships, announced the pricing of its initial public offering of 19,200,000 shares of its Series A common stock at an initial public offering price of $30.00 per share. The offering consists of 11,507,693 shares of Series A common stock offered by Klaviyo and 7,692,307 shares of Series A common stock to be sold by certain of Klaviyo’s existing stockholders. In addition, the underwriters will have a 30-day option to purchase up to an additional 2,880,000 shares of Series A common stock from certain of the selling stockholders at the initial public offering price, less underwriting discounts and commissions. The gross proceeds to Klaviyo from the offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by Klaviyo, are expected to be approximately $345.2 million. Klaviyo will not receive any proceeds from the sale of shares by the selling stockholders. The shares are expected to begin trading on the New York Stock Exchange under the ticker symbol “KVYO” on September 20, 2023. The offering is expected to close on September 22, 2023, subject to customary closing conditions. Goldman Sachs & Co. LLC, Morgan Stanley, and Citigroup are acting as lead book runners for the offering. Barclays, Mizuho, and William Blair are acting as joint book runners, Piper Sandler and Truist Securities are additionally acting as book runners, and Baird, Canaccord Genuity, Needham & Company, and TD Cowen are acting as co-managers.

Yesterday, Maplebear Inc. d/b/a “Instacart” announced the pricing of its initial public offering of 22,000,000 shares of its common stock, 14,100,000 of which are being sold by Instacart and 7,900,000 of which are being sold by certain selling stockholders, at a public offering price of $30.00 per share. Instacart will not receive any proceeds from any sale of shares by the selling stockholders. In addition, Instacart has granted the underwriters a 30-day option to purchase up to an additional 3,300,000 shares of its common stock at the initial public offering price, less underwriting discounts and commissions. The shares began trading on the Nasdaq Global Select Market on September 19, 2023, under the symbol “CART” & closed trading yesterday at $33.70, +12.33%. , but dropped today to $30.10,-10.68%The offering is expected to close on September 21, 2023, subject to customary closing conditions. Goldman Sachs & Co. LLC and J.P. Morgan are acting as lead book-running managers for the offering. BofA Securities, Barclays, and Citigroup are acting as additional book-running managers, and Baird, JMP Securities (A Citizens Company), LionTree, Oppenheimer & Co., Piper Sandler, SoFi, Stifel, Wedbush Securities, Blaylock Van, LLC, Drexel Hamilton, Loop Capital Markets, R. Seelaus & Co., LLC, Ramirez & Co., Inc., Stern, and Tigress Financial Partners are acting as co-managers for the offering.

On the small side of the market equities were off in general again today as the Russell 2000 closed at 1,810.10 (-.90%) as did the microcaps as the iShares Micro-Cap ETF (IWC) closed today at $101.48, -1.12%.

The beaten down biotech stocks ticked higher today as the SPDR S&P Biotech ETF (XBI) closed at $74.34, -2.17%, while the trading range gets tighter with the 52-wk high sitting now at $92.60 and the low is $72.44. However, the iShares Biotechnology ETF (IBB) closed at $124.63, -.86%. The 52-range is $113.37 – $138.74.

The iShares U.S. Healthcare ETF (IYH) closed at $277.42, -.06%.

Banks stocks moved lower again today as the SPDR S&P Regional Banking ETF (KRE) closed at $42.04, -.87% and the SPDR S&P Bank ETF (KBE) fell .85% closing at $37.28.

Around the crypto and precious metals’ tree, Bitcoin (BTC) traded to $27,157.94, +.19% over the last 24 hours at the time of this writing. Gold prices remain below 2k closing at $1,946, +$11/oz. & silver closed at $23.58, +$.25/oz. on the day.

The CBOE Volatility Index (^VIX) closed at $15.14, +7.30%.

FURTHER AFIELD

On September 12, Bausch Health Companies Inc. (NYSE:BHC, $8.34, +8.03% today) announced that following its approval by Health Canada the new treatment PrUCERIS® (budesonide) aerosol foam is now available across Canada to treat mild to moderate distal ulcerative colitis in adults.

Apellis Pharmaceuticals, Inc. (Nasdaq: APLS, $47, +.48%), a global biopharmaceutical company and leader in complement, recently announced that the company approved the grant of equity awards to 5 new employees with a grant date of September 1, 2023, as equity inducement awards outside of the company’s 2017 Stock Incentive Plan (but under the terms of the 2020 Inducement Stock Incentive Plan) and material to the employees’ acceptance of employment with the company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

Shares of C3.ai, Inc. (NYSE: AI), the Enterprise AI application software company, moved to close at $26.40,-3.19%. On Sept. 6. C3.ai announced financial results for its fiscal first quarter ended July 31, 2023 and missed expectations. However, Thomas M. Siebel, C3 AI CEO stated, “It is difficult to describe the scale of the increasing interest that we are seeing globally in enterprise AI adoption,We are experiencing strong traction with our enterprise AI applications and especially C3 Generative AI.” Total revenue for the quarter was $72.4 million, coming in at the high end of guidance of $70.0 million to $72.5 million.

Shares of ADT Inc. (ADT), the most trusted brand in smart home and small business security, closed at $5.94, -.67%. On Aug, 9, ADT reported results for the second quarter of 2023 and highlighted the following: Record high recurring monthly revenue balance and maintained record high customer retention, Improved capital efficiency with record revenue payback of 1.9 years, Positive net income with strong Adjusted EBITDA and operating cash flows, & announced agreement to divest commercial business for $1.6 billion unlocking significant shareholder value; net proceeds to be used for debt reduction.

Shares of Seanergy Maritime Holdings Corp. (SHIP), the only pure-play Capesize ship-owner publicly listed in the U.S. closed at $5.42, +-.18%. On Aug. 2, Seanergy announced its financial results for the second quarter and six months ended June 30, 2023. They highlighted that Fleet Time Charter Equivalent (“TCE” 3) overperformance of Baltic Capesize Index (“BCI”) by 20% in 2Q23 & 1H23, a Quarterly cash dividend of $0.025 per share for Q2 2023 – total cash dividends of $1.325 per share or $23.9 million declared since March 2022, a stock buyback of $1.6 million, or approximately 2% of its issued and outstanding shares – total repurchases of securities (common shares, convertible notes and warrants) of approximately $39.6 million since November 2021, an Agreement to acquire a 2011-built Newcastlemax dry bulk vessel through a 12-month bareboat charter with a purchase option, & $53.8 million in refinancings during the second quarter, on improved terms, adding $15.0 million of extra liquidity and removing any loan maturities until Q2 2025.

MEMES CENTRAL

Memes stock GameStop Corp. (GME) closed at $17.52, 0.0% as the shorts tied their ongoing daily battle today.

Shares of AMC, the largest movie exhibition company in the United States, the largest in Europe and the largest throughout the world with approximately 950 theaters and 10,500 screens across the globe, closed today at $8.16, -1.09%.

VP WATCHLIST UPDATES

Lantern (LTRN), closed at $3.84, -2.54% today, but has moved up to $4.03, +4.95% in the aftermarket. Lantern is an Artificial Intelligence (AI) firm that is transforming the cost, pace, and timeline of oncology drug discovery and development and specifically is developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical stage drug programs.

On September 18, Lantern announced that the United States Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for LP-284. LP-284 is being developed for the treatment of relapsed or refractory non-Hodgkin’s lymphoma (NHL), including mantle cell lymphoma (MCL) and double hit lymphoma (DHL) and other high-grade B-cell lymphomas (HGBL). Lantern expects to commence enrollment of patients for the first-in-human Phase 1 trial for LP-284 during the fourth quarter of 2023. Lantern estimates that LP-284 can have the potential to improve outcomes for 40,000 to 80,000 patients with blood cancers annually, with a global annual market potential of $4 Billion USD.

Panna Sharma is the President, CEO, and Board Member of Lantern Pharma Inc.

“This is now our second novel drug candidate to receive IND clearance from the FDA in the past 100 days, further validating our approach of leveraging AI and machine learning to accelerate the development of our pipeline. LP-284 holds blockbuster potential, and we have been able to expedite its journey from a concept to a first-in-human clinical trial in a highly efficient and cost-effective manner – less than 2.5 years and under approximately $2.7 million – underscoring the power and potential of our AI platform RADR® to accelerate oncology drug discovery and development. RADR® was used to unravel the mechanism of action of LP-284, prioritize its cancer indications, and generate machine-learning biomarker signatures that may be pivotal in selecting patients for future phases of the clinical trials. Our success-to-date with LP-284 reaffirms our commitment to harnessing the power of AI to transform cancer treatment and save lives,” stated Panna Sharma, Lantern’s President and CEO.

On September 8, Lantern’s Chief Executive Officer, Panna Sharma, delivered a presentation titled “How Artificial Intelligence Is Crushing Drug Discovery Times & Costs In Cancer” at a Tribe Public CEO Presentation & Q&A Event. The Event video is now published at the Tribe Public YouTube Channel that you may view now by clicking here.

On August 31, Lantern announced that it will present positive data highlighting the anti-tumor potency of its drug candidate LP-284 for non-Hodgkin’s lymphoma (NHL) at the Society of Hematologic Oncology (SOHO) Eleventh Annual Meeting occurring on Sept. 6 – 9, 2023, at the George R. Brown Convention Center in Houston, Texas. LP-284 is a small molecule with a synthetically lethal mechanism of action that preferentially damages cancer cells.. Lantern is developing LP-284 for the treatment of relapsed or refractory NHL, including Mantle Cell Lymphoma and Double Hit Lymphomas. Lantern expects to initiate Phase 1 clinical trials for LP-284 during Q4 of 2023. Lantern’s LP-284 program has been accelerated and de-risked using AI insights and biological modeling powered by RADR®. Lantern has been able to advance LP-284 from initial RADR® insights regarding anti-cancer activity and potential mechanisms of action in hematological cancers, to selection of specific subtypes of lymphomas with superior response, to late-stage IND enabling studies, and initial design of first in human clinical trials in less than two years.

Details of the poster presentation are listed below and can be found on the SOHO website. A full version of the poster will be available on Lantern’s website on September 11, 2023.

Title: LP-284 – Targeting Homologous Recombination Deficiencies in B-Cell Non-Hodgkin’s Lymphomas with the Novel Anti-Tumor Small Molecule LP-284
Date and Time: September 6, 2023, 6:00pm CT
Poster Number: ABCL-180
Presenter: Jianli Zhou, Ph.D., Lantern Pharma

On August 28, Lantern announced a substantial increase in the power and capabilities of RADR® focused on improving the drug development process for immune checkpoint inhibitors (ICIs). These capabilities are expected to address the multiple challenges facing the increased usage of ICIs in cancer therapy. Since gaining regulatory approval in 2011, ICIs have improved the lives of tens of thousands of cancer patients as either monotherapies, and more recently, in combination regimens with other therapies. The success of ICIs has resulted in multiple competing ICI molecules, often from the same class, in overlapping cancer indications. Additionally, recent clinical trial failures reveal headwinds to the desired expansion of ICIs for a broader range of cancers and patient groups. Currently, there are over 5,200 ongoing clinical trials involving ICIs, many of these lacking adequate biomarker strategies or guidance from AI enabled approaches to optimize the selection of patient responder populations. In a recent study presented at the 2023 ASCO meeting, RADR’s® algorithms demonstrated an 88% accuracy rate in predicting which melanoma (skin cancer) patients exhibiting resistance to anti-PD1 therapy will respond to Elraglusib, a GSK-3ϐ inhibitor being developed by Actuate Therapeutics, which previously entered into a multi-year research and development collaboration with Lantern Pharma to leverage the RADR® platform. The continued growth of ICIs, especially the approval of new ICIs, will be predicated on: 1) efficiently identifying new biomarker or molecular signatures for optimal patient selection, stratification, and management, and 2) rapidly developing combination regimens that overcome treatment challenges facing current and emerging solid and hematological cancer indications. Lantern’s latest RADR® AI developments will focus on addressing these challenges by building automated and highly scalable computational analytics to generate clinically relevant tumor-specific and tumor-agnostic molecular signatures to guide the identification and development of drug combinations that can prolong ICI durability of response and improve patient survival. These developments will leverage RADR® to uncover molecular drivers of response and resistance influencing ICI treatment outcomes by coupling pathway and network-based analytics with the simultaneous screening of millions of targets from complex clinical and biological data sets. This capability will be powered by tens of billions of new data points from immunotherapy and checkpoint inhibitor studies that Lantern has begun to add to its RADR® platform.

Lantern plans to deploy its new RADR® ICI predictive module with biopharma partners and to identify potential combinatorial strategies for LP-184 and LP-284, the first of Lantern’s drug candidates developed internally with the assistance of the RADR® AI platform. The ICI market is projected to reach $67.8 billion in annual sales by 2025, according to GlobalData, with future growth dependent on approvals from precision-based approaches guiding the development and positioning of new combination therapies.

On August 14, Lantern announced that it has received a notice of allowance from the United States Patent and Trademark Office (USPTO) covering a method of treatment for Atypical Teratoid Rhabdoid Tumor (ATRT) using LP-184, an aggressive and rapidly growing form of cancer of the central nervous system (CNS). LP-184 is the first of Lantern’s drug candidates developed by leveraging Lantern’s AI and ML platform, RADR®, to advance to a first-in-human Phase 1 basket trial. Lantern has rapidly advanced the clinical development of LP-184, activated the initial clinical trial sites, and has begun screening patients. Indications for the LP-184 trial are anticipated to include relapsed/refractory advanced pancreatic cancer, glioblastoma (GBM), brain metastases (brain mets), and multiple other recurring, advanced solid tumors with DNA damage response deficiencies. The dosage and safety data obtained in the Phase 1 trial will be used to advance the CNS indications, including ATRT, for a future Phase 2 trial to be sponsored by Lantern’s wholly-owned subsidiary, Starlight Therapeutics Inc. Globally, the aggregate annual market potential of LP-184’s target indications is estimated to be approximately $10+ billion, consisting of $5+ billion for CNS cancers and $6+ billion for other solid tumors. The U.S. Food and Drug Administration (FDA) has previously granted LP-184 Rare Pediatric Disease Designation and Orphan Drug Designation (ODD) for the treatment of pediatric patients with ATRT. The FDA has also previously granted LP-184 ODD for the treatment of pancreatic cancer and for the treatment of malignant glioma, including GBM. A notice of allowance is issued after the USPTO determines that the prosecution on the merits of a patent has been completed and grants the patent upon payment of the patent issuance fee. Additional corresponding patent applications are pending in Europe, Japan, Canada, and Australia.

Shares of Indaptus Therapeutics, Inc. (Nasdaq: INDP) closed at $3.50, -11.39% and is up 8.29% in the aftermarket. Indaptus is a company with the ability to harness both the body’s innate and adaptive immune responses, believes that they are uniquely positioned to revolutionize the treatment of cancer and certain infectious diseases. Indaptus Therapeutics has evolved from more than a century of immunotherapy advances. The Company’s novel approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and pathways and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system-activating signals that can be administered safely intravenously (i.v.). Indaptus’ patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria producing a multiple Toll-like receptor (TLR), Nucleotide oligomerization domain (Nod)-like receptor (NLR) and Stimulator of interferon genes (STING) agonist Decoy platform. The products are designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cells and pathways of innate and adaptive immunity. Decoy products represent an antigen-agnostic technology that have produced single-agent activity against metastatic pancreatic and orthotopic colorectal carcinomas, single agent eradication of established antigen-expressing breast carcinoma, as well as combination-mediated eradication of established hepatocellular carcinomas and non-Hodgkin’s lymphomas in standard pre-clinical models, including syngeneic mouse tumors and human tumor xenografts.

In pre-clinical studies tumor eradication was observed with Decoy products in combination with anti-PD-1 checkpoint therapy, low-dose chemotherapy, a non-steroidal anti-inflammatory drug, or an approved, targeted antibody. Combination-based tumor eradication in pre-clinical models produced innate and adaptive immunological memory, involved activation of both innate and adaptive immune cells, and was associated with induction of innate and adaptive immune pathways in tumors after only one i.v. dose of Decoy product, with associated “cold” to “hot” tumor inflammation signature transition. IND-enabling, nonclinical toxicology studies demonstrated safe i.v. administration without sustained induction of hallmark biomarkers of cytokine release syndromes, possibly due to passive targeting to liver, spleen, and tumor, followed by rapid elimination of the product. Indaptus’ Decoy products have also produced significant single agent activity against chronic hepatitis B virus (HBV) and chronic human immunodeficiency virus (HIV) infections in pre-clinical models.

On August 14, Indaptus announced financial results for the second quarter ended June 30, 2023 and provided a corporate update.

Jeffrey Meckler, CEO, Indaptus Therapuetics, Inc. (NASDAQ: INDP)

Jeffrey Meckler, Chief Executive Officer of Indaptus stated, “We have recently announced the completion of the first cohort of patients in our INDP-D101 trial evaluating Decoy20 for the treatment of solid tumors and receipt of authorization from the Safety Review Committee to advance into the second cohort. As previously announced, we are pleased to observe evidence of immune activation, along with short-lived adverse events consistent with Decoy20’s mechanism of action. We continue to analyze the data generated and anticipate that the data from the dose finding studies will guide the selection for the recommended Phase 2 dose for subsequent multi-dosing and combination studies, which are planned for 2024. An additional recent accomplishment is the appointment of industry veteran, Roger Waltzman, M.D., as our Chief Medical Officer. We anticipate benefiting from his expertise as we continue our Phase 1 trial and further develop the Decoy platform. In the meantime, we are prudently managing our cash position.”

Recent Corporate Highlights:

The Company announced the completion of the first cohort of its INDP-D101 trial and receipt of authorization from its Safety Review Committee to proceed into the second cohort of the Phase 1 trial.
A compound from the Company’s Decoy platform was presented in a poster titled, “A systemically administered killed bacteria-based multiple immune receptor agonist for pulsed anti-tumor immunotherapy,” at the American Association for Cancer Research Conference 2023. The poster highlighted that Decoy10 demonstrated 90% reduction of LPS-endotoxin activity and use of 100% killed, non-pathogenic bacteria.
The Company’s Chief Scientific Officer, Michael Newman, Ph.D., was named Chair for two of the three days of the 4th STING & TLR-Targeting Therapies Summit held in Boston from May 9 to 11, where he was also a featured speaker.
The Company received patent allowances for its Decoy immunotherapy platform in Brazil and India. The Indian patent allowance brought the number of countries in which the Company holds patent protection to 32.
Roger Waltzman, M.D. was appointed the Chief Medical Officer of Indaptus, effective August 7, 2023.

Learn more about Indaptus Therapeutics (NASDAQ: INDP) at the VP Watchlist page by clicking here.

INVO Bioscience, Inc. (NASDAQ: INVO, $1.01, -3.81%) is a healthcare services fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture (“IVC”) procedure it enables. On Aug. 14, INVO announced financial results for the second quarter ended June 30, 2023 and provided a business update. Q2 2023 Financial Highlights (all metrics compared to Q2 2022 unless otherwise noted):

Revenue was $315,902, an increase of 116% compared to $146,135.
Clinic revenue increased 126% to $254,364, compared to $112,358. All reported clinic revenue is derived from the Company’s INVO Center in Atlanta, Georgia, which is consolidated in the Company’s financial statements.
Revenue from all clinics, inclusive of both those accounted for as consolidated and under the equity method, was $712,433, an increase of 145% compared to $290,517.
Recent Operational and Strategic Highlights
Acquired Wisconsin Fertility Institute (WFI), a profitable Madison-based fertility center that primarily offers conventional IVF procedures and generated approximately $5.4 million in revenue and approximately $1.7 million of net income in 2022.
Acquisition further accelerates INVO’s transition to a healthcare services company and provides an opportunity to advance IVC volume and the ability to secure a greater share of total fertility cycle revenue.
Implemented expense reductions as part of go-forward plan to focus on its healthcare service strategy and a near-term path to profitability.
Buildout of the Company’s new Tampa, Florida clinic – Tampa Fertility Institute, an INVO Center – is nearing completion.
Raised approximately $4.5 million in gross proceeds in a public offering of common stock and warrants. The Company used approximately $2.15 million of proceeds for the initial payment for the WFI acquisition.
Received 510(k) FDA clearance for expanded use of the INVOcell device.

Q2 2023 Financial Highlights (all metrics compared to Q2 2022 unless otherwise noted)

Revenue was $315,902, an increase of 116% compared to $146,135.
Clinic revenue increased 126% to $254,364, compared to $112,358. All reported clinic revenue is derived from the Company’s INVO Center in Atlanta, Georgia, which is consolidated in the Company’s financial statements.
Revenue from all clinics, inclusive of both those accounted for as consolidated and under the equity method, was $712,433, an increase of 145% compared to $290,517.

Recent Operational and Strategic Highlights

Acquired Wisconsin Fertility Institute (WFI), a profitable Madison-based fertility center that primarily offers conventional IVF procedures and generated approximately $5.4 million in revenue and approximately $1.7 million of net income in 2022.
Acquisition further accelerates INVO’s transition to a healthcare services company and provides an opportunity to advance IVC volume and the ability to secure a greater share of total fertility cycle revenue.
Implemented expense reductions as part of go-forward plan to focus on its healthcare service strategy and a near-term path to profitability.
Buildout of the Company’s new Tampa, Florida clinic – Tampa Fertility Institute, an INVO Center – is nearing completion.
Raised approximately $4.5 million in gross proceeds in a public offering of common stock and warrants. The Company used approximately $2.15 millionof proceeds for the initial payment for the WFI acquisition.
Received 510(k) FDA clearance for expanded use of the INVOcell device.

Management Commentary

“We believe we have successfully transformed INVO into a rapidly growing, innovative healthcare services company which allows us to help accelerate IVC volume and obtain a greater share of the total fertility cycle revenue. The closing of the WFI acquisition last week, coupled with the rapid 145% revenue growth in our existing INVO Center’s during this past quarter, should position our clinic operations to be cash flow positive in the third quarter of this year. Further, we have implemented a number of expense reductions as part of our go-forward plan to focus on our healthcare service strategy, which when coupled with the elimination of substantive costs associated with our successful 510(k) submission, should drive the business towards overall positive operating cash flow in 2024,” commented Steve Shum, CEO of INVO.

Today, shares of Borqs Technologies, Inc. (Nasdaq: BRQS), a global provider of 5G wireless solutions, Internet of Things (IoT) solutions, and innovative clean energy, with global operations in the U.S., India, and China closed at $.1886, +.59%.

On Aug. 22, Borqs announced the Committee on Foreign Investment in the United States (CFIUS) has granted the Company an extension from the original deadline of September 15, 2023 to January 1, 2024 to complete the divestment of its subsidiary, Holu Hou Energy LLC (HHE). As previously announced, the Company was mandated by CFIUS to divest its ownership in the solar energy storage subsidiary, HHE, due to national security concerns. Subsequently, Cantor Fitzgerald & Co., a nationally reputable investment firm, was engaged by the Company to initiate and manage the sales process of the Company’s ownership in HHE and has received considerable interest from potential buyers. Over the coming months, the Company anticipates that the due diligence process will be completed, and the said transaction is targeted to be finalized by the end of the year. Mr. Pat Chan, CEO of Borqs stated, “Once we receive the funds from selling our interest in HHE, Borqs will continue to invest into futuristic technologies, especially in artificial intelligence based IoT products. We will also consider a share buyback program and/or a special dividend payout depending on the amount of cash to be received in order to enhance our shareholder value. We will provide further updates to our shareholders with regards to the HHE divestment during the next few months.”

On July 17, Borqs announced its plans to develop an AI-enabled smart watch as part of its expansion strategy into artificial intelligence (AI) for the U.S. market. The AI-enabled smart watch is positioned as an Edge AI device. According to NVIDIA, “Edge AI is the deployment of AI applications in devices throughout the physical world. It’s called “edge AI” because the AI computation is done near the user at the edge of the network, close to where the data is located, rather than centrally in a cloud.” (https://resources.nvidia.com/en-us-it-resources-blogs/what-is-edge-ai) Borqs AI-enabled smart watch will be based on Android and is wirelessly connected via Wifi/BT and cellular networks. It will make use of the AI capability on the watch chipset platform to perform the training and inference of machine learning for the sensors on the watch. The watch will also support ChatGPT or similar AGI capabilities as an intelligent voice assistant. Read more here.

On July 6, Borqs Technologies announced that together with SkyCentrics, they have launched the next generation CTA-2045 ECOPORT communication products. The next-generation products are more price competitive and feature-rich than the current generation products and have significantly better cellular coverage with the use of internal and external antennas. Borqs and SkyCentrics announced their strategic partnership in 2021. The partnership includes joint research & development, sales, and promotion, as well as, Borqs’ investment into SkyCentrics. It will leverage Borqs’ expertise in mobile IoT and 5G technologies. Borqs has years of manufacturing experience in making products worldwide, and has manufactured products for the U.S. mobile operators and Fortune 500 companies. SkyCentrics is an expert in the CTA-2045 and demand response technologies and will be responsible for the CTA-2045 software, ECOPORT certification, and cloud functionality with its Demand Response Energy & Asset Management (DREAM) platform.

On July 20, InMed (INM, $.8133, -4.32%) provided a commercial and manufacturing update on its subsidiary BayMedica LLC (“BayMedica”), a leading supplier of bioidentical rare cannabinoids to the Health and Wellness (“H&W”) market. Highlighting the following: $2.3M revenues (unaudited) in Q4 2023, representing 123% increase quarter over quarter (“QoQ”), Optimized and scaled up manufacturing processes over the last 12 months to meet increasing demand, & Third consecutive quarter with significant revenue growth. Eric A. Adams, InMed’s President and CEO stated, “We are very encouraged to see another strong quarter with (unaudited) revenues in excess of $2.3M, representing our third consecutive quarter with significant revenue growth. As demand for minor cannabinoids continues to increase, we see a potential path for BayMedica to become a profitable standalone business subsidiary and contribute margin to the pharmaceutical R&D parent.”

Shares of Atossa Therapeutics (ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology with a current focus on breast cancer and lung injury caused by cancer treatments, closed at $.77, -2.99%.

On Aug. 14, Atossa announced financial results for the quarter ended June 30, 2023, and provided an update on recent company developments highlighted by the following: Achieved significant enrollment milestones in three ongoing Phase 2 clinical trials, Broadened patent protection for proprietary (Z)-endoxifen, Strengthened management team with appointment of Greg Weaver as Chief Financial Officer, & Ended second quarter 2023 with $99.4 million of cash and cash equivalents.

Economic Reports

On Monday, the NAHB Housing Market Index report confirmed a move lower to 45 in September.

On Tuesday, the Aughts housing starts report confirmed that we achieved level or 1.283M since June 2020, however the building permits report confirmed that we were up 6.9% M/M at 1.543M & single unit permits moved up 2%.

On Wednesday, the weekly MBA Mortgage Applications Index report that shoed a moved up to 5.4%, while refinance applications jumped a cool 13% & purchase applications bumped up 2%. The weekly EIA crude oil inventories report confirmed a 2.14M barrel draw.

Investing & Inspiration

“To begin, begin.” – William Wordsworth

“You can find peace amidst the storms that threaten you.” – Joseph B. Wirthlin

“Everything that is made beautiful and fair and lovely is made for the eye of one who sees.” – Rumi

“The secret of business is to know something that nobody else knows.” – Aristotle Onassis

“Life is the art of drawing without an eraser.” – John W. Gardner

“Learning never exhausts the mind.” – Leonardo da Vinci

“Live as brave men; and if fortune is adverse, front its blows with brave hearts.” – Marcus Tullius Cicero

“It is not in the stars to hold our destiny but in ourselves.” – William Shakespeare

“The end of labor is to gain leisure.” – Aristotle

“Though we travel the world over to find the beautiful, we must carry it with us or we find it not.” – Ralph Waldo Emerson

“Any sufficiently advanced technology is indistinguishable from magic.” – Arthur C. Clarke

“Good questions outrank easy answers.” – Paul Samuelson

“Experience is the teacher of all things.” – Julius Caesar

To see things in the seed, that is genius.” – Lao Tzu

“Lend yourself to others, but give yourself to yourself.” – Michel de Montaigne

“People are not disturbed by things, but by the view they take of them.” – Epictetus

“Knowledge comes, but wisdom lingers.” – Alfred Lord Tennyson

“Hitch your wagon to a star.” – Ralph Waldo Emerson

“If fear is cultivated it will become stronger, if faith is cultivated it will achieve mastery.” – John Paul Jones

“Great minds discuss ideas; average minds discuss events; small minds discuss people.” – Eleanor Roosevelt

“Happiness is a direction, not a place.” – Sydney J. Harris

“Don’t let making a living prevent you from making a life.” – John Wooden

“The secret of your future is hidden in your daily routine.” – Mike Murdock

“We boil at different degrees.” – Clint Eastwood

“If we open a quarrel between past and present, we shall find that we have lost the future.” – Winston Churchill

“Hope is patience with the lamp lit.” – Tertullian

“All human wisdom is summed up in two words; wait and hope.” – Alexandre Dumas

“Forgiveness is the key to action and freedom.” – Hannah Arendt

“The unexamined life is not worth living.” – Socrates

“I never think of the future – it comes soon enough.” – Albert Einstein

“Today you are you! That is truer than true! There is no one alive who is you-er than you!” – Dr. Seuss

“We live in a rainbow of chaos.” – Paul Cezanne

“Real knowledge is to know the extent of one’s ignorance.” – Confucius

“Better keep yourself clean and bright; you are the window through which you must see the world.” – George Bernard Shaw

“Life consists not in holding good cards but in playing those you hold well.” – Josh Billings

“The traveler sees what he sees, the tourist sees what he has come to see.” – Gilbert K. Chesterton

“Goodness is the only investment that never fails.” – Henry David Thoreau

“The return we reap from generous actions is not always evident.” – Francesco Guicciardini

“Courage is knowing what not to fear.”– Plato

“Freedom means the opportunity to be what we never thought we would be.” – Daniel J. Boorstin

“Fishes live in the sea, as men do a-land; the great ones eat up the little ones.” – William Shakespeare

“A man is what he thinks about all day long.” – Ralph Waldo Emerson

“There are two ways of spreading light: to be the candle or the mirror that reflects it.” – Edith Wharton

“We cannot live only for ourselves. A thousand fibers connect us with our fellow men.” – Herman Melville

“Childhood is a short season” – Helen Hayes

“Formula for success: rise early, work hard, strike oil.” – J. Paul Getty

“The hardest arithmetic to master is that which enables us to count our blessings.” – Eric Hoffer

“I fear not the man who has practiced 10,000 kicks once, but I fear the man who has practiced one kick 10,000 times.” – Bruce Lee

“There are no shortcuts in evolution.” – Louis D. Brandeis

“Hope is the only bee that makes honey without flowers.” – Robert Green Ingersoll

“Our happiness depends on wisdom all the way.” – Sophocles

“Life is the art of drawing without an eraser.” – John W. Gardner

“Give light and people will find the way.” – Ella Baker

“Without craftsmanship, inspiration is a mere reed shaken in the wind.” – Johannes Brahms

“Either move or be moved.” – Ezra Pound

“Time is but the stream I go a-fishing in.” – Henry David Thoreau

“It’s easy to make a buck. It’s a lot tougher to make a difference.” – Tom Brokaw

“If you can’t stand the heat, get out of the kitchen.” – Harry S Truman

“Remember upon the conduct of each depends the fate of all.” – Alexander the Great

“Silence is the sleep that nourishes wisdom.” – Francis Bacon“

“Have patience. All things are difficult before they become easy.” – Saadi

“No man ever steps in the same river twice, for it’s not the same river and he’s not the same man.” – Heraclit

“An effort made for the happiness of others lifts above ourselves.” – Lydia M. Child

“It is amazing what you can accomplish if you do not care who gets the credit.” – Harry S Truman

“If you do not think about your future, you cannot have one.” – John Galsworthy

“Your own mind is a sacred enclosure into which nothing harmful can enter except by your permission.” – Arnold Bennett

“There is always risk involved. You can’t be a capitalist only when there are investment profits but then a socialist when you experience losses.” – Cristina Kirchner

“I hear, I know. I see, I remember. I do, I understand.” – Confucius

“He has achieved success who has worked well, laughed often, and loved much.” – Elbert Hubbard

“Nobody who ever gave his best regretted it.” – George Halas

“We must not allow other people’s limited perceptions to define us.” – Virginia Satir

“There is a wisdom of the head, and a wisdom of the heart.” – Charles Dickens

“Perfection is the child of time.” – Joseph Hall

“No matter what people tell you, words and ideas can change the world.” – Robin Williams

“Find something you’re passionate about and keep tremendously interested in it.” – Julia Child

“The glow of one warm thought is to me worth more than money.” – Thomas Jefferson

“Between stimulus and response there is a space. In that space is our power to choose our response. In our response lies our growth and our freedom.” – Viktor E. Frankl

“Progress lies not in enhancing what is, but in advancing toward what will be.” – Khalil Gibran

“Cherish all your happy moments; they make a fine cushion for old age.” – Booth Tarkington

“The most effective way to do it, is to do it.” – Amelia Earhart

“If you’re going through hell, keep going.” – Winston Churchill

“The only sure weapon against bad ideas is better ideas.” – Alfred Whitney Griswold

“Words are, of course, the most powerful drug used by mankind.” – Rudyard Kipling

“The more things change, the more they are the same.” – Alphonse Karr

“Of all possessions a friend is the most precious.” – Herodotus

“Everything has beauty, but not everyone sees it.” – Confucius

“The man who is swimming against the stream knows the strength of it.” – Woodrow Wilson

“Success is the sum of small efforts – repeated day in and day out.” – Robert Collier

“You exist only in what you do.” – Federico Fellini

“Most people have the will to win, few have the will to prepare to win.” – Bobby Knight

“The true art of memory is the art of attention.” – Samuel Johnson

The secret of happiness is something to do.” – John Burroughs

“A will finds a way.” – Orison Swett Marden

“To live is to think.” – Marcus Tullius Cicero

“The sea hath fish for every man.” – William Camden

“What is called genius is the abundance of life and health.” – Henry David Thoreau

“Prosperity tries the fortunate, adversity the great.” – Rose Kennedy

“No one can figure out your worth but you.” – Pearl Bailey

“Let there be work, bread, water and salt for all.” – Nelson Mandela

“When one paints an ideal, one does not need to limit one’s imagination.” – Ellen Key

“Perfection is attained by slow degrees; it requires the hand of time.” – Voltaire

“Time passes irrevocably.” – Virgil

“The world of reality has its limits; the world of imagination is boundless.” – Jean-Jacques Rousseau

“The time you enjoy wasting is not wasted time.” – Bertrand Russell

“Mastering others is strength. Mastering yourself is true power.” – Lao Tzu

“You begin with the possibilities of the material.” – Robert Rauschenberg

“If you live to be a hundred, I want to live to be a hundred minus one day so I never have to live without you.” – A. A. Milne

“The only way to discover the limits of the possible is to go beyond them into the impossible.” – Arthur C. Clarke

“Do not dwell in the past, do not dream of the future, concentrate the mind on the present moment.” – Buddha

“Curiosity will conquer fear even more than bravery will.” – James Stephens

“There are years that ask questions and years that answer.” – Zora Neale Hurston

“The best and most beautiful things in the world cannot be seen or even touched – they must be felt with the heart.” – Helen Keller

“Every failure is a step to success.” – William Whewell

“If you aren’t fired with enthusiasm, you will be fired with enthusiasm.” – Vince Lombardi

“Either you run the day or the day runs you.” – Jim Rohn

“A computer once beat me at chess, but it was no match for me at kick boxing.” – Emo Philips

“I attribute my success to this – I never gave or took any excuse.” – Florence Nightingale

“I can’t change the direction of the wind, but I can adjust my sails to always reach my destination.” – Jimmy Dean

“If you fell down yesterday, stand up today.” – H. G. Wells

“The world breaks everyone, and afterward, some are strong at the broken places.” – Ernest Hemingway

“The quality, not the longevity, of one’s life is what is important.” – Martin Luther King, Jr.

“You can’t expect to hit the jackpot if you don’t put a few nickels in the machine.” – Flip Wilson

“Put your heart, mind, and soul into even your smallest acts. This is the secret of success.” – Swami Sivananda

“If the highest aim of a captain were to preserve his ship, he would keep it in port forever.” – Thomas Aquinas

“The secret of your future is hidden in your daily routine.” – Mike Murdock

“Happiness is not a matter of intensity but of balance, order, rhythm and harmony.” – Thomas Merton

“Seek the lofty by reading, hearing and seeing great work at some moment every day.” – Thornton Wilder

“Once you bring life into the world, you must protect it. We must protect it by changing the world.” – Elie Wiesel

“Let us permit nature to have her way. She understands her business better than we do.” – Michel de Montaigne

“Great minds have purposes; others have wishes.” – Washington Irving

“The great thing about getting older is that you don’t lose all the other ages you’ve been.” – Madeleine L’Engle

“If you’re alive, there’s a purpose for your life.” – Rick Warren

“Dream in a pragmatic way.” – Aldous Huxley

“The works must be conceived with fire in the soul but executed with clinical coolness.” – Joan Miro

“Memories are the key not to the past, but to the future.” – Corrie Ten Boom

“Great minds discuss ideas; average minds discuss events; small minds discuss people.” – Eleanor Roosevelt

“Failure will never overtake me if my determination to succeed is strong enough.” – Og Mandino

“I think about my work every minute of the day.” – Jeff Koons

“I restore myself when I’m alone.” – Marilyn Monroe

“Success is peace of mind which is a direct result of self-satisfaction in knowing you did your best to become the best you are capable of becoming.” – John Wooden

“Courage is found in unlikely places.” – J. R. R. Tolkien

“The first wealth is health.” – Ralph Waldo Emerson

“Courage is found in unlikely places.” – J. R. R. Tolkien

“Do what you can, with what you have, where you are.” – Theodore Roosevelt

“A good beginning makes a good end.” – Louis L’Amour

“What you do today can improve all your tomorrows.” – Ralph Marston

“One that would have the fruit must climb the tree.” – Thomas Fuller

“Joy in looking and comprehending is nature’s most beautiful gift.” – Albert Einstein

“The future belongs to those who believe in the beauty of their dreams.” – Eleanor Roosevelt

“Never go to bed mad. Stay up and fight.” – Phyllis Diller

“The undertaking of a new action brings new strength.” – Richard L. Evans

“It’s kind of fun to do the impossible.” – Walt Disney

“Real riches are the riches possessed inside.” – B. C. Forbes

“Reject your sense of injury and the injury itself disappears.” – Marcus Aurelius

“It is not enough to have a good mind; the main thing is to use it well.” – Rene Descartes

“A leader is one who knows the way, goes the way, and shows the way.” – John C. Maxwell

“It takes an endless amount of history to make even a little tradition.” – Henry James”It’s not what you pay a man, but what he costs you that counts.” – Will Rogers

“Halloween is not only about putting on a costume, but it’s about finding the imagination and costume within ourselves.” – Elvis Duran

“Everything in the world may be endured except continual prosperity.” – Johann Wolfgang von Goethe

“Where is all the knowledge we lost with information?” – T. S. Eliot

“All I ask is the chance to prove that money can’t make me happy.” – Spike Milligan

“Out of difficulties grow miracles.” – Jean de la Bruyere

“Nine-tenths of wisdom is being wise in time.” – Theodore Roosevelt

“Time is money.” – Benjamin Franklin

“I can, therefore I am.” – Simone Weil

“Where there is no vision, there is no hope.” – George Washington Carver

“Greatness is a road leading towards the unknown.” – Charles de Gaulle

“Kind words do not cost much. Yet they accomplish much.” – Blaise Pascal

“The world is round so that friendship may encircle it.” – Pierre Teilhard de Chardin

“Our deeds determine us, as much as we determine our deeds.” – George Eliot

The greatest use of a life is to spend it on something that will outlast it.” – William James

“Happiness is not something ready made. It comes from your own actions.” – Dalai Lama

“If opportunity doesn’t knock, build a door.” – Milton Berle

“I would define, in brief, the poetry of words as the rhythmical creation of Beauty.” – Edgar Allan Poe

“There are people who have money and people who are rich.” – Coco Chanel

“The young man knows the rules, but the old man knows the exceptions.” – Oliver Wendell Holmes, Sr.

“The past always looks better than it was. It’s only pleasant because it isn’t here.” – Finley Peter Dunne

“With the new day comes new strength and new thoughts.” – Eleanor Roosevelt

“Give me the luxuries of life and I will willingly do without the necessities.” – Frank Lloyd Wright

“To begin, begin.” – William Wordsworth

“You can find peace amidst the storms that threaten you.” – Joseph B. Wirthlin

“Nobody made a greater mistake than he who did nothing because he could do only a little.” – Edmund Burke

“Whenever you find yourself on the side of the majority, it is time to pause and reflect.” – Mark Twain

“Adapt or perish, now as ever, is nature’s inexorable imperative.” – H. G. Wells

“Won’t be long before we view gasoline cars the same way we view steam engines today.” – Elon Musk

“The aim of life is to live, and to live means to be aware, joyously, drunkenly, serenely, divinely aware.” – Henry Miller

“It is not in the stars to hold our destiny but in ourselves.” – William Shakespeare“Opportunity is missed by most people because it is dressed in overalls and looks like work.” – Thomas A. Edison“Experience is one thing you can’t get for nothing.” – Oscar Wilde

“Any sufficiently advanced technology is indistinguishable from magic.” – Arthur C. Clarke

“Good questions outrank easy answers.” – Paul Samuelson

“Thinking: the talking of the soul with itself.” – Plato

“I don’t think of all the misery but of the beauty that still remains.” – Anne Frank

“All money is a matter of belief.” – Adam Smith

“People are not disturbed by things, but by the view they take of them.” – Epictetus

“Uncertainty is seen to retard investment independently of considerations of risk or expected return.” – Ben Bernanke

“I never called my work an ‘art’. It’s part of show business, the business of building entertainment.” – Walt Disney

“Hitch your wagon to a star.” – Ralph Waldo Emerson

“The greatest remedy for anger is delay.” – Lucius Annaeus Seneca

“Great minds discuss ideas; average minds discuss events; small minds discuss people.” – Eleanor Roosevelt

“Act as if what you do makes a difference. It does.” – William James

“Success – keeping your mind awake and your desire asleep.” – Walter Scott

“If I had to live my life again, I’d make the same mistakes, only sooner.” – Tallulah Bankhead

“When one must, one can.” – Charlotte Whitton

“Wealth consists not in having great possessions, but in having few wants.” – Epictetus

“If we open a quarrel between past and present, we shall find that we have lost the future.” – Winston Churchill

“Hope is patience with the lamp lit.” – Tertullian

“A single sunbeam is enough to drive away many shadows.” – Francis of Assisi

“With the past, I have nothing to do; nor with the future. I live now.” – Ralph Waldo Emerson

“Laziness may appear attractive, but work gives satisfaction.” – Anne Frank

“I never think of the future – it comes soon enough.” – Albert Einstein

“Hope is but the dream of those who wake.” – Matthew Prior

“The more sand that has escaped from the hourglass of our life, the clearer we should see through it.” – Jean Paul

“Real knowledge is to know the extent of one’s ignorance.” – Confucius

“Better keep yourself clean and bright; you are the window through which you must see the world.” – George Bernard Shaw

“Nothing great in the world has ever been accomplished without passion.” – Georg Wilhelm Friedrich Hegel

“History is a vast early warning system.” – Norman Cousins

“We first make our habits, and then our habits make us.” – John Dryden

“The traveler sees what he sees, the tourist sees what he has come to see.” – Gilbert K. Chesterton

“Adventure is worthwhile.” – Aesop

“We must build dikes of courage to hold back the flood of fear.” – Martin Luther King, Jr.

“The return we reap from generous actions is not always evident.” – Francesco Guicciardini

“Courage is knowing what not to fear.” – Plato

“Science may never come up with a better office communication system than the coffee break.” – Earl Wilson

“Progress was all right. Only it went on too long.” – James Thurber

“If you would know strength and patience, welcome the company of trees.” – Hal Borland

“We aim above the mark to hit the mark.” – Ralph Waldo Emerson

“Hope is being able to see that there is light despite all of the darkness.” – Desmond Tutu

“Our chief want is someone who will inspire us to be what we know we could be.” – Ralph Waldo Emerson

“Patience is a virtue, and I’m learning patience. It’s a tough lesson.” – Elon Musk

“Great things are done when men and mountains meet.” – William Blake

“The man who has no imagination has no wings.” – Muhammad Ali

“Formula for success: rise early, work hard, strike oil.” – J. Paul Getty

“Action is the foundational key to all success.” – Pablo Picasso

“Hope is like the sun, which, as we journey toward it, casts the shadow of our burden behind us.” – Samuel Smiles

“The backbone of surprise is fusing speed with secrecy.” – Carl von Clausewitz

“There are no shortcuts in evolution.” – Louis D. Brandeis

“I am fascinated by what is beautiful, strong, healthy, what is living. I seek harmony.” – Leni Riefenstahl

“If one advances confidently in the direction of his dreams, and endeavors to live the life which he has imagined, he will meet with a success unexpected in common hours.” – Henry David Thoreau

“Waste no more time arguing about what a good man should be. Be one.” – Marcus Aurelius

“It is during our darkest moments that we must focus to see the light.” – Aristotle Onassis

“Courage is fear holding on a minute longer.” – George S. Patton

“You must be the change you wish to see in the world.” – Mahatma Gandhi

“Don’t judge each day by the harvest you reap but by the seeds that you plant.” – Robert Louis Stevenson

“It is in the character of very few men to honor without envy a friend who has prospered.” – Aeschylus

“Life is a series of natural and spontaneous changes. Don’t resist them – that only creates sorrow. Let reality be reality. Let things flow naturally forward in whatever way they like.” – Lao Tzu

“The more you praise and celebrate your life, the more there is in life to celebrate.” – Oprah Winfrey

“Anything simple always interests me.” – David Hockney

“He who angers you conquers you.” – Elizabeth Kenny

“Concision in style, precision in thought, decision in life.” – Victor Hugo

“The secret of genius is to carry the spirit of the child into old age, which means never losing your enthusiasm.” – Aldous Huxley

“View health as an investment, not an expense.” – John Quelch

“The most effective way to do it, is to do it.” – Amelia Earhart
“Man needs his difficulties because they are necessary to enjoy success.” – A. P. J. Abdul Kalam
“Do not dwell in the past, do not dream of the future, concentrate the mind on the present moment.” – Buddha
“Nobody made a greater mistake than he who did nothing because he could do only a little.” – Edmund Burke
“You must do the things you think you cannot do.”- Eleanor Roosevelt
“Success is dependent on effort.” – Sophocles
“Nobody who ever gave his best regretted it.” – George Halas
“Lots of people want to ride with you in the limo, but what you want is someone who will take the bus with you when the limo breaks down.” ~ Oprah Winfrey
“And when I breathed, my breath was lightning.” – Black Elk
“Moderation is the silken string running through the pearl chain of all virtues.” – Joseph Hall
“You are the sum total of everything you’ve ever seen, heard, eaten, smelled, been told, forgot – it’s all there. Everything influences each of us, and because of that I try to make sure that my experiences are positive.” – Maya Angelou
“If you want a guarantee, buy a toaster.” – Clint Eastwood
“We are an impossibility in an impossible universe.” – Ray Bradbury
“If you think in terms of a year, plant a seed; if in terms of ten years, plant trees; if in terms of 100 years, teach the people.” – Confucius
“I’d rather attempt to do something great and fail than to attempt to do nothing and succeed.” – Robert H. Schuller
“Do your little bit of good where you are; it’s those little bits of good put together that overwhelm the world.” Desmond Tutu
“It takes considerable knowledge just to realize the extent of your own ignorance.” – Thomas Sowell
“Do not dwell in the past, do not dream of the future, concentrate the mind on the present moment.” – Buddha”
Surprise is the greatest gift which life can grant us.” – Boris Pasternak
“Trust in dreams, for in them is hidden the gate to eternity.” – Khalil Gibran
“Always be yourself, express yourself, have faith in yourself, do not go out and look for a successful personality and duplicate it.” – Bruce Lee
“All life is an experiment. The more experiments you make the better.” – Ralph Waldo Emerson
“There are no secrets to success. It is the result of preparation, hard work, and learning from failure.” – Colin Powell
“There is more to life than increasing its speed.” – Mahatma Gandhi
“Your attitude is like a box of crayons that color your world. Constantly color your picture gray, and your picture will always be bleak. Try adding some bright colors to the picture by including humor, and your picture begins to lighten up.” – Allen Klein
“Definiteness of purpose is the starting point of all achievement.” – W. Clement Stone
“Success usually comes to those who are too busy to be looking for it.” – Henry David Thoreau
“In matters of truth and justice, there is no difference between large and small problems, for issues concerning the treatment of people are all the same.” – Albert Einstein
“Life is too short for long-term grudges.” – Elon Musk
“There cannot be a crisis next week. My schedule is already full.” – Henry Kissinger
“Success consists of getting up just one more time than you fall.” – Oliver Goldsmith
“The Earth is the cradle of humanity, but mankind cannot stay in the cradle forever.” – Konstantin Tsiolkovsky
“Ours is a world of nuclear giants and ethical infants. We know more about war that we know about peace, more about killing that we know about living.” – Omar N. Bradley
“Beauty surrounds us, but usually we need to be walking in a garden to know it.” – Rumi
“But man is not made for defeat. A man can be destroyed but not defeated.” – Ernest Hemingway
“Don’t watch the clock; do what it does. Keep going.” – Sam Levenson
“Let there be work, bread, water and salt for all.” – Nelson Mandela
“The social object of skilled investment should be to defeat the dark forces of time and ignorance which envelope our future.” – John Maynard Keynes
“A successful society is characterized by a rising living standard for its population, increasing investment in factories and basic infrastructure, and the generation of additional surplus, which is invested in generating new discoveries in science and technology.” – Robert Trout
“I know not with what weapons World War III will be fought, but World War IV will be fought with sticks and stones.” – Albert Einstein
“It is the fight alone that pleases us, not the victory.” – Blaise Pascal
“If you can’t describe what you are doing as a process, you don’t know what you’re doing.” – W. Edwards Deming
“Never interrupt your enemy when he is making a mistake.” – Napoleon Bonaparte
“Be sure you put your feet in the right place, then stand firm.” – Abraham Lincoln
“Without investment there will not be growth, and without growth there will not be employment.” – Muhtar Kent
“You have to do your own growing no matter how tall your grandfather was.” – Abraham Lincoln
“Victory has a thousand fathers, but defeat is an orphan.” – John F. Kennedy
“Delete the negative; accentuate the positive!” – Donna Karan
“It’s crazy how fast time flies and how things progress.” – Nathan Chen
“The world is a dangerous place to live; not because of the people who are evil, but because of the people who don’t do anything about it.” – Albert Einstein
“Life isn’t about finding yourself. Life is about creating yourself.” – George Bernard Shaw
“Everything has beauty, but not everyone sees it.” – Confucius
“A man must be big enough to admit his mistakes, smart enough to profit from them, and strong enough to correct them.” – John C. Maxwell
“Walking with a friend in the dark is better than walking alone in the light.” – Helen Keller
“A man who dares to waste one hour of time has not discovered the value of life.” – Charles Darwin
“The greater danger for most of us lies not in setting our aim too high and falling short; but in setting our aim too low, and achieving our mark.” – Michelangelo
“Progress is man’s ability to complicate simplicity.” – Thor Heyerdahl
“I like to encourage people to realize that any action is a good action if it’s proactive and there is positive intent behind it.” – Michael J. Fox
“Nothing is impossible, the word itself says ‘I’m possible’!” – Audrey Hepburn
“But investment in space stimulates society, it stimulates it economically, it stimulates it intellectually, and it gives us all passion.” – Bill Nye
“Bitcoin, in the short or even long term, may turn out be a good investment in the same way that anything that is rare can be considered valuable. Like baseball cards. Or a Picasso.” – Andrew Ross Sorkin
“Life is a tragedy when seen in close-up, but a comedy in long-shot.” – Charlie Chaplin
“No matter what you’re going through, there’s a light at the end of the tunnel and it may seem hard to get to it but you can do it and just keep working towards it and you’ll find the positive side of things.” – Demi Lovato
“Infrastructure investment in science is an investment in jobs, in health, in economic growth and environmental solutions.” – Oren Etzioni
“Educating our children and giving them the skills they need to compete in a global economy is a smart investment in our country’s future.” – Sheldon Whitehouse
“Know thy self, know thy enemy. A thousand battles, a thousand victories.” – Sun Tzu
“If one does not know to which port one is sailing, no wind is favorable.” – Lucius Annaeus Seneca
“Beware of missing chances; otherwise it may be altogether too late some day.” – Franz Liszt
“The sofa is a really important investment for anybody, and I don’t mean financially. You need to find a really great sofa that can transition with you, and you can build from there.” – Jeremiah Brent
“There is no investment you can make which will pay you so well as the effort to scatter sunshine and good cheer through your establishment.” – Orison Swett Marden
“Nothing in life is to be feared, it is only to be understood. Now is the time to understand more, so that we may fear less.” – Marie Curie
“There is little that can withstand a man who can conquer himself.” – Louis XIV
“In tennis, you strike a ball just after the rebound for the fastest return. It’s the same with investment.” – Masayoshi Son
“A camel makes an elephant feel like a jet plane.” – Jackie Kennedy
“The advance of technology is based on making it fit in so that you don’t really even notice it, so it’s part of everyday life.” – Bill Gates
“Success depends upon previous preparation, and without such preparation there is sure to be failure.” – Confucius, Chinese
“Coming together is a beginning; keeping together is progress; working together is success.” – Edward Everett Hale
“Never do anything against conscience even if the state demands it.”– Albert Einstein
“Education is not only a ladder of opportunity, but it is also an investment in our future.” – Ed Markey
“The true measure of a man is how he treats someone who can do him absolutely no good.” – Samuel Johnson
“In my view, the biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital. Not only is the mere drop in stock prices not risk, but it is an opportunity. Where else do you look for cheap stocks?” – Li Lu
“A successful society is characterized by a rising living standard for its population, increasing investment in factories and basic infrastructure, and the generation of additional surplus, which is invested in generating new discoveries in science and technology.” – Robert Trout
“The best preparation for tomorrow is doing your best today.” – H. Jackson Brown, Jr.
“Friendship marks a life even more deeply than love. Love risks degenerating into obsession, friendship is never anything but sharing.” – Elie Wiesel
“Investing in women’s lives is an investment in sustainable development, in human rights, in future generations – and consequently in our own long-term national interests.” – Liya Kebede
“Success isn’t measured by money or power or social rank. Success is measured by your discipline and inner peace.” – Mike Ditka
“No matter how many goals you have achieved, you must set your sights on a higher one.” – Jessica Savitch
“Start where you are. Use what you have. Do what you can.”– Arthur Ashe
“The secret of getting ahead is getting started.” – Mark Twain
“The amount of work and the amount of both physical and emotional investment it takes to get to the top.” – Drew Bledsoe